Shots:

• Wave will receive $170M up front incl. $120M in cash & $50M in equity investment along with research funding related to target validation activities. The transaction is expected to close in Q1’23
• For WVE-006 & GSK’s eight programs, Wave is eligible for ~$225M & ~$130-$175M in development & launch milestones, ~$300M & $200M in sales-related milestones along with royalties. GSK to get an exclusive license globally to WVE-006 for alpha-1 antitrypsin deficiency along with development & commercialization responsibilities after completion of the first-in-patient study. Wave will lead all preclinical, regulatory, manufacturing & clinical activities for WVE-006
• Wave to get the right to advance ~3 preclinical programs for targets identified by GSK & GSK will have the right to advance ~8 programs using Wave’s PRISM platform & GSK’s expertise. The collaboration incl. an option to extend the research for ~3 additional yrs.

Ref: GSK | Image: GSK